Optimizing Anti-EGFR Therapy in Colorectal Cancer.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 26463710.
- Also identified by DOI 10.1158/1078-0432.CCR-15-1768.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Treatment with anti-EGFR monoclonal antibodies has been successfully integrated in the continuum of care for metastatic colorectal cancer. The major challenge is the identification of patients who would benefit from treatment. Currently, the best predictor of efficacy is the absence of mutations in KRAS and NRAS genes. Clin Cancer Res; 21(24); 5415-6. ©2015 AACR.See related article by Peeters et al., p. 5469.
Medical subject headings
- ErbB Receptors
- ras Proteins